Phase I clinical trial of survivin‐derived peptide vaccine therapy for patients with advanced or recurrent oral cancer - Miyazaki, Akihiro; Kobayashi, Junichi; Torigoe, Toshihiko; Hirohashi, Yoshihiko; Yamamoto, Takashi; Yamaguchi, Akira; Asanuma, Hiroko; Takahashi, Akari; Michifuri, Yoshitaka; Nakamori, Kenji; Nagai, Itaru; Sato, Noriyuki; et al. (Cancer science, 2011)
Keywords: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm - immunology; Antigens, Neoplasm - therapeutic use; Biological and medical sciences; Cancer Vaccines - therapeutic use; Epitopes, T-Lymphocyte - immunology; Female; Humans; Immunotherapy, Active - methods; Inhibitor of Apoptosis Proteins; Male; Medical sciences; Microtubule-Associated Proteins - immunology; Microtubule-Associated Proteins - therapeutic use; Middle Aged; Mouth Neoplasms - immunology; Mouth Neoplasms - therapy; Otorhinolaryngology. Stomatology; Tumors; Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology; Vaccines, Subunit - therapeutic use; Human; Relapse; Oral cancer; Peptides; Stomatology; Vaccine; Malignant tumor; Survivin; Cancerology; Treatment; Apoptosis inhibitory protein; Phase I trial; Advanced stage; Oral cavity disease; Cancer